Tag Archives: QURE
Chardan Capital Thinks uniQure’s Stock is Going to Recover
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (QURE – Research Report) on August 4 and set a price target of $80.00. The company’s shares closed last Monday at $41.36, close to its 52-week low of $36.20.
Credit Suisse Thinks uniQure’s Stock is Going to Recover
In a report released yesterday, Martin Auster from Credit Suisse maintained a Buy rating on uniQure (QURE – Research Report), with a price target of $76.00. The company’s shares closed last Friday at $41.33, close to its 52-week low of
Thursday’s Highlights at Noon: Kandi Technologies (KNDI), MobileIron (MOBL), Sangamo Biosciences (SGMO), Dynavax (DVAX), uniQure (QURE)
So far Thursday, July 30, NASDAQ is up 5.66% and the S&P is up 1.5%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Kandi Technologies (KNDI – Research Report), MobileIron (MOBL – Research
Analysts Have Conflicting Sentiments on These Healthcare Companies: uniQure (NASDAQ: QURE) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on uniQure (QURE – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report). uniQure (QURE) uniQure received a Hold rating and a $61.00 price target from
Mizuho Securities Keeps Their Buy Rating on uniQure (QURE)
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on uniQure (QURE – Research Report), with a price target of $90.00. The company’s shares closed last Wednesday at $63.27. According to TipRanks.com, Yang ‘s ranking
uniQure (QURE) Receives a Rating Update from a Top Analyst
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on uniQure (QURE – Research Report) today and set a price target of $105.00. The company’s shares closed last Monday at $56.50. According to TipRanks.com, Amusa is a top 100 analyst
